IN8bio Inc. (NASDAQ: INAB)
$0.85
-0.0080 ( -0.93% ) 59.9K
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Market Data
Open
$0.85
Previous close
$0.86
Volume
59.9K
Market cap
$38.56M
Day range
$0.83 - $0.87
52 week range
$0.65 - $2.48
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | May 09, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |
def | Proxies and info statements | 14 | Apr 26, 2024 |
10-k | Annual reports | 116 | Mar 14, 2024 |
8-k | 8K-related | 14 | Mar 14, 2024 |
4 | Insider transactions | 1 | Feb 08, 2024 |
4 | Insider transactions | 1 | Feb 08, 2024 |
4 | Insider transactions | 1 | Feb 08, 2024 |
4 | Insider transactions | 1 | Feb 08, 2024 |
4 | Insider transactions | 1 | Feb 08, 2024 |